RallyBio: Proof-of-Concept Achieved for Antibody to Prevent Thrombocytopenia

 RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects --

-- Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT --

-- Company Expects to Present Results at a Scientific Conference in 2023 --

https://www.biospace.com/article/releases/rallybio-announces-proof-of-concept-achieved-for-rlyb212-a-novel-monoclonal-anti-hpa-1a-antibody-to-prevent-fetal-and-neonatal-alloimmune-thrombocytopenia/